We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Novel Method Developed to Diagnose Buruli Ulcer

By LabMedica International staff writers
Posted on 09 Nov 2016
A Buruli ulcer is a subcutaneous skin disease listed among the neglected tropical diseases, and early case detection and management is very important to reduce morbidity and the accompanied characteristic disfiguring nature of the disease.

The diagnosis of Buruli ulcer (BU) is based on clinical evidence that can lead to misdiagnosis, and microbiological confirmation is essential to reduce abuse of drugs, since the anti-mycobacterial drugs are also used for the treatment of tuberculosis.

Scientists associated with the University of Ghana (Accra, Ghana) developed a method to diagnose BU using aptamers that bind to the lipid particle mycolactone, which is produced by the causative agent Mycobacterium ulcerans. More...
The team collected swabs and fine needle aspirations from 41 patients suspected of having BU. The samples were analyzed by polymerase chain reaction for the IS2404 sequence repeat, culture, and an enzyme-linked oligonucleotide assay (ELONA). Aptamers that bind to mycolactone were isolated by the systematic evolution of ligands by exponential enrichment (SELEX) process. To measure their affinity and specificity to mycolactone, the selected aptamers were screened by means of isothermal titration calorimetry. The ELONA assays measured at absorbance 450 nm using a MultiSkan Go plate reader (Thermo Fisher Scientific, Waltham MA, USA).

The investigators found that five out of the nine selected aptamers bound significantly to mycolactone, of these, three were able to distinguish between mycolactone producing mycobacteria, M. marinum and other bacteria whilst two others also bounded significantly to M. smegmatis. Their dissociation constants were in the micro-molar range. Fourteen swab samples tested positive for both culture and IS2404 PCR whilst positivity observed among the aptamers ranged from one to seven. The aptamer-based assay was used in a case control study and had a sensitivity of 50% and a specificity of 100%.

The aptamer-based test had a sensitivity of 50%, which is comparable to that of microscopy and culture, whilst the specificity is comparable to that of the IS2404 PCR. The authors concluded that their preliminary proof-of-concept indicates that diagnosis of Buruli Ulcer Disease with ribonucleic acid (RNA) aptamers is feasible and can be used as point of care upon incorporation into a diagnostic platform. The study was published on October 24, 2016, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
University of Ghana
Thermo Fisher Scientific

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.